Context Therapeutics

Advancing T Cell Engagers for Solid Tumors

[Context Therapeutics @Context_Tx]

Context acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. $CNTX https://t.co/sKMAtFSWl4

[Context Therapeutics @Context_Tx]

📣Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
🗓️Phase 1 initiation for CT-202 trial expected in third quarter of 2026. $CNTX

https://t.co/kh2vULxMWK

[Context Therapeutics @Context_Tx]

@Context_Tx announces Q1 2026 earnings
⏰ CTIM-76 Ph1a interim data June 2026
⏰ CT-95 Ph1a interim data Sept 2026
✅ CT-202 Ph1 initiation Q3 2026
💲Expected runway into mid-2027 $CNTX

https://t.co/JycV4M0agD

[Context Therapeutics @Context_Tx]

This morning at #AACR26, colleagues from @Context_Tx will present a poster discussion on CT-202, a Nectin‑4 × CD3 T‑cell engager (TCE). Poster link: First in Human Development of CT-202 — Context Therapeutics

[Context Therapeutics @Context_Tx]

This morning at #AACR26, colleagues from @Context_Tx will present a poster discussion on CT-202, a Nectin‑4 × CD3 T‑cell engager (TCE). CT-202 is Context’s 3rd asset to enter clinical development since 2025.

Poster: https://t.co/2n2XOCZe32

[Context Therapeutics @Context_Tx]

Today @Context_Tx reported its full year 2025 operating and financial results. Our lead program, CTIM-76, is on track to present interim Phase 1a data in June 2026.

Read our full press release here: https://t.co/pEbFK7mxvF

[Context Therapeutics @Context_Tx]

🚨Context Therapeutics ($CNTX) highlights CT-95 and CT-202 programs at #SITC2025 Meeting
✅ Both are potentially best-in-class
✅ Conditional activation at the tumor
👍 Complete tumor resolution in mice
👀View here: Publications — Context Therapeutics https://t.co/dqdNNb2wGi

[Context Therapeutics @Context_Tx]

🚨 Context Therapeutics $CNTX Q3 2025 Highlights: 
✅ CTIM-76 demonstrates encouraging antitumor activity and safety 
✅ CT-95 is approaching target dose levels  
💰 $76.9M cash and cash equivalents as of Sept 30, 2025 
✅ Expected cash runway into 2027

[Context Therapeutics @Context_Tx]

Context Therapeutics is excited to share that we will be presenting at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting!

#SITC2025 #Immunotherapy #TCE

https://t.co/1lRxxvtMs9

[Context Therapeutics @Context_Tx]

Our CEO, Martin Lehr, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference tomorrow, September 3rd. #cantor, #TCE, $CNTX

[Context Therapeutics @Context_Tx]

Context Therapeutics $CNTX Q2 2025 Highlights:
✅ CTIM-76 & CT-95 Phase 1 dose-escalation trials ongoing
✅ $83.5M cash and cash equivalents as of June 30, 2025
✅ Expected cash runway into 2027

Read more here: https://t.co/amIBs1u1oQ

#Biotech #Immunotherapy #CancerRes #TCE

[Context Therapeutics @Context_Tx]

$CNTX announces CTIM-76 Trial in Progress poster at #ASCO25
✅Dosing Cohort 3 of Phase 1 trial
✅ CLDN6 x CD3 TCE for ovarian, endometrial & testicular cancers
✅Initial data expected 1H 2026
📍Poster: June 2, Hall A, 1:30 PM CDT
🔗 https://t.co/LCrQ4hSWUf
#Biotech

[Context Therapeutics @Context_Tx]

We’re excited to welcome Dr. Karen Chagin as Chief Medical Officer at $CNTX, effective June 9, 2025!

With 10+ years leading T cell therapy development at Adaptimmune and Tmunity, she brings deep clinical expertise at a key time for Context.

Read more: https://t.co/VVaGiuFN8e

[Context Therapeutics @Context_Tx]

🚨 Context Therapeutics $CNTX Q1 2025 Highlights:
✅ CTIM-76 & CT-95 in Phase 1 trials
✅ $89.4M cash and cash equivalents as of March 31, 2025
✅ Expected cash runway into 2027
#Biotech #Immunotherapy #CancerResearch #TCellEngagers

Read more here:https://t.co/oDLfWQfTB9

[Context Therapeutics @Context_Tx]

🚨 We’re excited to welcome Jennifer Dashnau, PhD, MBA as SVP of Technical Operations at Context Therapeutics!

Welcome to the team, Jennifer! 👏

#Biotech #Leadership #Immunotherapy #TCellEngagers #ContextTherapeutics #Oncology #WomenInSTEM

[Context Therapeutics @Context_Tx]

The Context team presented preclinical and translational data for CT-95, our mesothelin-targeting T cell engager, at #AACR2025! View the poster here: https://t.co/AiGY4KHFZw
#Immunotherapy #Biotech $CNTX

[Context Therapeutics @Context_Tx]

📢 Context Therapeutics CEO Martin Lehr will join the T Cell Engagers panel at #AACR25!
🗓 Thursday, April 24 | 🕠 5:45–6:45 PM CT | 📍 Room W192
Moderated by Leerink Partners, the panel includes leaders from J&J, Zymeworks
#Biotech #Immunotherapy #TCellEngagers

[Context Therapeutics @Context_Tx]

🚀Another big milestone for $CNTX: First patient dosed in Phase 1 clinical trial of CT-95, our mesothelin x CD3 T cell engaging bispecific antibody targeting solid tumors. CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 💡
#Immunotherapy

[Context Therapeutics @Context_Tx]

Join $CNTX at two premier events! Catch our presentation on Tuesday, April 8 at 10 AM ET during the Stifel Virtual Targeted Oncology Forum, and meet us at the 24th Annual Needham Virtual Healthcare Conference with 1x1 meetings on April 8th #Biotech

[Context Therapeutics @Context_Tx]

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors.

Andy is the former EVP, Chief Strategy Officer of Horizon Pharma (acquired for $28Bn) and Senior Partner at Bain & Company.

[Context Therapeutics @Context_Tx]

Our CEO, Martin Lehr, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:00am ET.

#PiperSandler, #oncology, T cell engager